Caris Diagnostics Providing KRAS Mutational Analysis for Colon Cance...(th confirmed KRAS mutations responded to...),Health

Date:6/24/2008

th confirmed KRAS mutations responded to Erbitux, whereas tumors shrank in 40% of those patients with the wild type (normal) KRAS gene. In another research study conducted in Belgium and published in March, Erbitux was ineffective in treating any of the 42 patients with a mutation, but proved effective in 27 of 66 patients with wild type KRAS. Amgen has also published a study noting that their drug Vectibix only works in patients with wild type KRAS. In Europe, Vectibix is only approved for patients who have wild type KRAS.

"The data are very compelling; research has clearly implicated KRAS as a vital biomarker for the assessment of response to Erbitux and Vectibix," said Dr. Daniel Von Hoff, Executive Director of Caris MPI's Pharmaceutical Services division, TGen Physician in Chief, and Chief Scientific Officer of US Oncology. "I think the oncology community is looking forward to having this type of information available in order to continue to develop more targeted, personalized treatment plans for patients."

KRAS mutation analysis is also being offered as part of Caris Dx's Target Now(TM) testing program. Target Now is an oncology testing service that utilizes cutting-edge molecular profiling techniques, including DNA microarray, advanced immunohistochemistries (IHC), fluorescent in-situ hybridization (FISH) and sequencing analysis, to provide molecular profiling information about a malignancy as an aid to a patient's oncologist. Each test report provides information on the molecular targets present in the cancer specimen for which there are believed to be associated therapies based on published literature. Furthermore, the report provides other additional information on the molecular profile of the patient's cancer.

At the beginning of 2008, Caris Diagnostics acquired Caris MPI in order to offer a single source solution to physicians seeking the highest quality medical opinions coupled with the most advanced molecular information available o
'/>"/>

SOURCE Caris Diagnostics Copyright©2008 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4
Related medicine news :

1. Caris Diagnostics Announces Addition of Leading Dermatopathologist to Expand Subspecialty Expertise
2. FDA Approves SOMA(R) (carisoprodol) 250 mg
3. Quest Diagnostics to Speak at the Jefferies 2nd Annual Healthcare Conference
4. Quest Diagnostics to Provide Diagnostic Testing Services for the Women of Ireland through Irelands First Nationwide Cervical-Cancer Screening Program
5. Escalon(R) Enhances Position Within IVD Reagent Market with Strategic Acquisition of JAS Diagnostics
6. Johnson & Johnson Reviews Growth Strategies for Medical Devices & Diagnostics and Consumer Businesses
7. Johnson & Johnson to Host Medical Devices & Diagnostics and Consumer Business Review
8. Quest Diagnostics Chooses Roches Fully Automated, Real-Time HIV-1 Viral Load Monitoring Test For Its Customers in Laboratories Nationwide
9. Quest Diagnostics Is Named Best Employer For Healthy Lifestyles
10. Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008
11. Allegro Diagnostics Announces Publication in Cancer Prevention Research of Prediction Model for Lung Cancer Diagnosis Integrating Clinical and Genomic Features